- Home
- NDLS vs DTIL Comparison
NDLS vs DTIL Comparison
Compare NDLS & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- DTIL
- Stock Information
- Founded
- NDLS 1995
- DTIL 2006
- Country
- NDLS United States
- DTIL United States
- Employees
- NDLS N/A
- DTIL N/A
- Industry
- NDLS Restaurants
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- DTIL Health Care
- Exchange
- NDLS Nasdaq
- DTIL Nasdaq
- Market Cap
- NDLS 45.2M
- DTIL 56.2M
- IPO Year
- NDLS 2013
- DTIL 2019
- Fundamental
- Price
- NDLS $0.90
- DTIL $5.20
- Analyst Decision
- NDLS Strong Buy
- DTIL Strong Buy
- Analyst Count
- NDLS 2
- DTIL 2
- Target Price
- NDLS $3.00
- DTIL $47.00
- AVG Volume (30 Days)
- NDLS 79.4K
- DTIL 161.1K
- Earning Date
- NDLS 05-07-2025
- DTIL 05-15-2025
- Dividend Yield
- NDLS N/A
- DTIL N/A
- EPS Growth
- NDLS N/A
- DTIL N/A
- EPS
- NDLS N/A
- DTIL 1.04
- Revenue
- NDLS $495,670,000.00
- DTIL $68,696,000.00
- Revenue This Year
- NDLS $4.57
- DTIL N/A
- Revenue Next Year
- NDLS $1.29
- DTIL $30.20
- P/E Ratio
- NDLS N/A
- DTIL $4.95
- Revenue Growth
- NDLS N/A
- DTIL 40.98
- 52 Week Low
- NDLS $0.55
- DTIL $3.61
- 52 Week High
- NDLS $2.36
- DTIL $13.44
- Technical
- Relative Strength Index (RSI)
- NDLS 38.19
- DTIL 51.79
- Support Level
- NDLS $0.81
- DTIL $5.00
- Resistance Level
- NDLS $1.09
- DTIL $5.97
- Average True Range (ATR)
- NDLS 0.07
- DTIL 0.35
- MACD
- NDLS 0.00
- DTIL -0.02
- Stochastic Oscillator
- NDLS 21.07
- DTIL 29.90
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.